First asset utilizing Adcentrx’s ADC platform to receive IND clearance Planned Phase 1a/1b clinical trial expected to begin in 2H 2023 SAN DIEGO, July 17, 2023 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced that the...Continue reading
Author: AvantGen
AvantGen Appoints Jordon Wang as Chief Operating Officer
AvantGen, a San Diego based biotechnology company with a superior yeast display technology for facile...Continue reading
AvantGen awarded contract from NIH to expedite the commercialization of its AccuRate COVID-19 SelfCheck OTC test
AvantGen, a San Diego based biotechnology company with a superior yeast display technology for facile...Continue reading
Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates
SAN DIEGO, Feb. 14, 2022 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology...Continue reading
AvantGen receives an award from the NIH/RADx to commercialize its anti-SARS-CoV-2 nucleocapsid antibodies for ultra-high sensitivity lateral flow assay development
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) — AvantGen, a San Diego-based biotech, is a leader...Continue reading
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
SAN DIEGO–(BUSINESSWIRE)–AvantGen, Inc., a San Diego-based biotechnology company with an...Continue reading
Avantgen Develops Novel Human Antibodies to Diagnose SARS-COV-2 Infection and Treat COVID-19
SAN DIEGO, CA.– AvantGen, Inc., a privately-held San Diego-based biotechnology company...Continue reading
Avantgen Enters a Strategic Collaboration Agreement to Develop Novel Anti-Cancer Therapeutic with Its NK Cell Engager Technology
AvantGen’s NK cell engager technology now available for partnering on a target-exclusive basis...Continue reading
AvantGen And Tanabe Research Laboratories Expand Collaboration For Therapeutic Antibody Discovery
Under the terms of the collaboration, AvantGen is responsible for generating novel...Continue reading
AvantGen Awarded SBIR Phase II Contract to Develop High-Affinity, Anti-Peptide Rabbit Monoclonal Antibodies for SISCAPA Assays from the NIH/NCI
Antibodies with high affinity and specificity suitable for cancer biomarker measurements are essential...Continue reading